| Balance Sheets | 2025-09-30 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 1,660,105 | |||
| Accounts receivable, net | 717,823 | |||
| Inventories | 628,177 | |||
| Research and development tax incentive receivable | 924,062 | |||
| Assets held for sale | 66,020 | |||
| Other current assets | 488,182 | |||
| Total current assets | 4,484,369 | |||
| Property and equipment, net | 271,745 | |||
| Operating lease right-of-use assets | 1,808,892 | |||
| Intangibles, net | 3,473,303 | |||
| Total assets | 10,038,309 | |||
| Accounts payable and accrued expenses | 3,992,427 | |||
| Current portion of operating lease liabilities | 362,801 | |||
| Current employee benefit liabilities | 567,059 | |||
| Notes payable | 139,787 | |||
| Total current liabilities | 5,062,074 | |||
| Employee benefit liabilities, less current portion | 100,041 | |||
| Operating lease liabilities, less current portion | 1,449,265 | |||
| Total liabilities | 6,611,380 | |||
| Common stock, 0.01 par value, 100,000,000 shares authorized, 9,098,473 and 9,098,357 shares issued and outstanding, respectively, as of september 30, 2025 7,323,377 and 7,323,261 shares issued and outstanding, respectively, as of june 30, 2025 | 90,985 | |||
| Treasury stock, at cost, 116 shares as of september 30, 2025 and june 30, 2025 | 1 | |||
| Additional paid-in capital | 69,325,542 | |||
| Accumulated deficit | -65,516,071 | |||
| Accumulated other comprehensive loss | -279,228 | |||
| Total consolidated intelligent bio solutions inc. equity | 3,621,227 | |||
| Non-controlling interest | -194,298 | |||
| Total shareholders equity | 3,426,929 | |||
| Total liabilities and shareholders equity | 10,038,309 | |||
INTELLIGENT BIO SOLUTIONS INC. (INBS)
INTELLIGENT BIO SOLUTIONS INC. (INBS)